PLX
Protalix BioTherapeutics, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
Signal stack
Where each data set points today.
- InsidersNO TRADES
No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.
- InstitutionsBULLISH
Q3 2026: 15 added (0 new), 10 trimmed or exited.
- AnalystsBULLISH
4 of 5 rate it Buy or better. Every target is above the price.
- EstimatesFALLING
Current-quarter EPS estimate −$0.010 → −$0.020 over 90 days.
- Short sellersSTEADY
Short interest −0.8% to 3.48M shares. 6.2 days to cover, ≈4.3% of shares.
- TrendUPTREND
12% above its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| DIMENSIONAL FUND ADVISORS LP | ADD | $2.0M |
| MARSHALL WACE, LLP | TRIM | $832.9K |
| Russell Investments Group, Ltd. | DOUBLED | $686.0K |
| MORGAN STANLEY | ADD | $269.3K |
| Walleye Capital LLC | DOUBLED | $194.7K |
| JPMORGAN CHASE & CO | TRIM | $108.0K |
| BARCLAYS PLC | DOUBLED | $88.1K |
| BNP PARIBAS FINANCIAL MARKETS | ADD | $57.2K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
5 analystsPrice is below the lowest target. Median implies +296%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Sep 9, 2026 | HC Wainwright & Co. REITERATE | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Boudes Pol F Director Sep 3, 2026 | AWARD | 8,500 sh |
Boudes Pol F Director Sep 3, 2026 | AWARD | 17,000 sh |
Bashan Dror PRESIDENT AND CEO Sep 3, 2026 | AWARD | 160,000 sh |
Bashan Dror PRESIDENT AND CEO Sep 3, 2026 | AWARD | 320,000 sh |
Elze Christian Director Sep 3, 2026 | AWARD | 8,500 sh |
Elze Christian Director Sep 3, 2026 | AWARD | 17,000 sh |
Naos Yaron Sr. VP & COO Sep 3, 2026 | AWARD | 56,000 sh |
Ben Zvi Shmuel Director Sep 3, 2026 | AWARD | 8,500 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.02 | -$0.04–$0.01 | -100.0% | $12.9M |
| Next Q | $0.01 | $0.01–$0.01 | +0.0% | $15.8M |
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | None | None | No data | $76.3M |
Short side
FINRA· Oct 30, 2026SecBot reports
3 filings · 0 bullish · 0 bearish · 3 neutral- NEUTRAL 8-KNov 10, 2026
Protalix reported Q3 2026 total revenue of $21.9M, up 22.8% YoY from $17.9M, and net income of…
Revenue growth is driven by Elfabrio sales through Chiesi, but the $25M milestone in Q1 2026 inflates year-to-date comparisons. Watch for Q4 2026 revenue to confirm whether the full-year guidance…
- NEUTRAL SC 13GOct 15, 2026
HOLD Alapkezelo Zrt., a Hungarian investment fund management company, filed a Schedule 13G…
Monitor for any future conversion to a 13D filing, which would signal a shift from passive to activist intent. For now, this is a routine passive disclosure with no immediate catalyst.
- NEUTRAL 8-KAug 12, 2026
Protalix reported Q2 2026 revenue of $19.9M, beating the $12.9M consensus, and EPS of $0.05…
The revenue beat was driven by product sales growth, but the company's guidance implies a significant H2 slowdown to hit the $78M-$83M full-year target. Monitor Q3 and Q4 revenue trends for Elfabrio…
All PLX filing & press-release reports (3)
- 8-K reportNov 10, 2026
- SC 13G reportOct 15, 2026
- 8-K reportAug 12, 2026